Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Bone Miner Res. 2012 Jul;27(7):1462–1470. doi: 10.1002/jbmr.1603

Figure 2. Proposed treatment regimen and clinical course.

Figure 2

A) Proposed Regimen. Dosing regimen and monitoring schedule are indicated. Denosumab was to be given monthly at an initial dose of 1 mg/kg. Dose escalations were planned at three month intervals (blue arrows) to 1.25 mg/kg, 1.5 mg/kg, and 1.75 mg/kg. The patient was evaluated by his local endocrinologist monthly and at NIH every three months. Mineral panels were monitored weekly for the first three months and then monthly (not shown). Bone turnover markers were monitored monthly (not shown). The scale represents months. D = dose of denosumab, TV = tumor volume, AS = arm spam, XR = Hand XR, DE = dental exam, BX = bone biopsy. B) Clinical Course. The periods for the administration of analgesics, supplemental phosphorus, calcium and calcitriol, denosumab, and bisphosphonate treatment (pamidronate or zoledronic acid) are indicated by the transverse lines, and cessation by the double vertical lines. Time points for biopsy, fracture and start of hypercalcemia are indicated. The scale represents months.